source
- Abivax reports ulcerative colitis trial cancer rates align with expectationsAbivax released new data from its Phase 3 trial of an ulcerative colitis candidate. The data show that the number of cancer cases observed was within the range normally expected for ulcerative col…
- Biotech firms raise record funds in 2026, with $2.1 bn round for Isomorphic LabsAfter a few slow years, the biotech financing landscape is showing signs of recovery, though investors remain cautious about where they place capital. A recent PharmaVoice reader poll found that 2…